study_id,author,first_dose_only,location_id,location_id2,location_name,location_name2,vac_before_booster,vaccine_developer,variant,symptom_severity,severity,sample_size,age_start,age_end,efficacy_mean,efficacy_lower,efficacy_upper,booster,vemt,mean_time_since_vaccination,start_interval,end_interval,sev_severity,mid_point1,mid_point,group_analysis,vaccine_type,study_id2,e_mean
521,Chemaitelly H,0,151,151,Qatar,Qatar delta,"",Moderna,Delta,infection,infetcion,,20,70,0.092,-0.091,0.245,0,0,,21,24,infection,22.5,22.5,Non_Omicron,mRNA,521&Qatar delta&Delta&infetcion&20&70,-0.0088888888888889
555,Starrfelt J,0,90,90,Norway,Norway 2 delta,"",Pfizer & BioNTech,Delta,infection,infection,,18,85,0.082,0.034,0.128,0,0,,34,42,infection,38,38,Non_Omicron,mRNA,555&Norway 2 delta&Delta&infection&18&85,-0.02
558,Voko Z,0,48,48,Hungary,Hungary delta 18-64,"",Pfizer & BioNTech,Delta,infection,infection,,18,64,0.06,-0.023,0.034,0,0,,35,42,infection,38.5,38.5,Non_Omicron,mRNA,558&Hungary delta 18-64&Delta&infection&18&64,-0.0444444444444445
